文献

J-GLOBAL ID：202202261357963666   整理番号：22A0911233

COVID-19ワクチンと血液学的異常のリスク: コホート内症例対照研究と自己管理症例シリーズ研究【JST・京大機械翻訳】

COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study

著者 (29件)： Sing Chor-Wing (Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China) ,  Sing Chor-Wing (Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Special Administrative Region, China) ,  Tang Casey Tze Lam (Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China) ,  Chui Celine Sze Ling (Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Special Administrative Region, China) ,  Chui Celine Sze Ling (School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China) ,  Chui Celine Sze Ling (School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China) ,  Fan Min (Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China) ,  Lai Francisco Tsz Tsun (Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Special Administrative Region, China) ,  Lai Francisco Tsz Tsun (Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China) ,  Li Xue (Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Special Administrative Region, China) ,  Li Xue (Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China) ,  Li Xue (Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China) ,  Wan Eric Yuk Fai (Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Special Administrative Region, China) ,  Wan Eric Yuk Fai (Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China) ,  Wan Eric Yuk Fai (Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China) ,  Wong Carlos King Ho (Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Special Administrative Region, China) ,  Wong Carlos King Ho (Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China) ,  Wong Carlos King Ho (Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China) ,  Chan Esther Wai Yin (Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Special Administrative Region, China) ,  Chan Esther Wai Yin (Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China) ,  Hung Ivan Fan Ngai (Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China) ,  Hung Ivan Fan Ngai (Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Government of the Hong Kong Special Administrative Region, Hong Kong Special Administrative Region, China) ,  Leung Anskar Yu-Hung (Division of Haematology, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China) ,  Cheung Ching-Lung (Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China) ,  Cheung Ching-Lung (Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Special Administrative Region, China) ,  Wong Ian Chi Kei (Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Special Administrative Region, China) ,  Wong Ian Chi Kei (Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China) ,  Wong Ian Chi Kei (Expert Committee on Clinical Events Assessment Following COVID-19 Immunization, Department of Health, The Government of the Hong Kong Special Administrative Region, Hong Kong Special Administrative Region, China) ,  Wong Ian Chi Kei (Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK)
資料名： American Journal of Hematology  (American Journal of Hematology)
巻： 97  号： 4  ページ： 470-480  発行年： 2022年 
JST資料番号： E0721B  ISSN： 0361-8609  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： アメリカ合衆国 (USA)  言語： 英語 (EN)

抄録/ポイント： いくつかの研究は,コロナウイルス病2019(COVID-19)に対するワクチン接種後の血液学的異常を報告した。COVID-19ワクチン(CoronaVacとBNT162b2)と血液学的異常との関連を評価した。Hong Kong Hospital Authority and Health of Heality関心の転帰は血小板減少症,白血球減少症および好中球減少症であった。調整オッズ比(aORs),発生率比(IRRs)および95%信頼区間(CIs)を,条件付きロジスティック回帰を用いて推定した。全体で,1643419人がCOVID-19ワクチン接種を受けた(738609CoronaVac;904810BNT162b2)。CoronaVacおよびBNT162b2ワクチン接種後に,それぞれ457および422症例を同定した。CoronaVacでは,血小板減少症,白血球減少症および好中球減少症の発生率は,10000用量あたり2.51,1.08および0.15であった。BNT162b2に対して,対応する発生率は,10000用量あたり1.39,1.17および0.26であった。10000のCOVID-19症例の発生率は,それぞれ1254,2341,および884であった。著者らは,BNT162b2(aOR 1.58,95%CI 1.24~2.02;0-14,IRR 2.21;95%CI 1.59~3.08)の2回目の投与後の白血球減少のリスク増加のみを観察した。CoronaVacワクチン接種後の血液学的異常のリスク増加はなかった。著者らは,BNT162b2の2回目の投与後の白血球減少のリスク増加を観察した。しかし,発生率は重症急性呼吸器症候群コロナウイルス2(SARS-CoV-2)感染後の発生率よりはるかに低かった。CoronaVacと血液学的異常の間に関連はなかった。COVID-19に対するワクチン接種の利点は,血液学的異常のリスクをまだ凌駕する。Copyright 2022 Wiley Publishing Japan K.K. All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： 白血球減少症 ,  *ワクチン ,  比率 ,  予防接種 ,  血小板減少症 ,  好中球減少症 ,  投与 ,  自己管理
準シソーラス用語： コロナウイルス ,  *血液学 ,  ロジスティック回帰分析 ,  *症例研究 , 【Automatic Indexing@JST】

分類 (2件)： 免疫療法薬・血液製剤の臨床への応用  (GW22020O) ,  感染症・寄生虫症一般  (GD01010H)

タイトルに関連する用語 (7件)： ワクチン ,  血液学 ,  リスク ,  コホート内症例対照研究 ,  自己管理 ,  症例シリーズ ,  研究